112 related articles for article (PubMed ID: 21997230)
1. Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function.
Morse MA; Hobeika A; Serra D; Aird K; McKinney M; Aldrich A; Clay T; Mourich D; Lyerly HK; Iversen PL; Devi GR
Cancer Gene Ther; 2012 Jan; 19(1):30-7. PubMed ID: 21997230
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets.
Pyzik M; Piccirillo CA
J Leukoc Biol; 2007 Aug; 82(2):335-46. PubMed ID: 17475784
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.
Brillard E; Pallandre JR; Chalmers D; Ryffel B; Radlovic A; Seilles E; Rohrlich PS; Pivot X; Tiberghien P; Saas P; Borg C
Exp Hematol; 2007 Mar; 35(3):416-25. PubMed ID: 17309822
[TBL] [Abstract][Full Text] [Related]
4. Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile.
De Somer L; Fevery S; Bullens DM; Rutgeerts O; Lenaerts C; Mathieu C; Boon L; Kasran A; Waer M; Billiau AD
Immunol Lett; 2010 Sep; 133(1):49-53. PubMed ID: 20600326
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
[TBL] [Abstract][Full Text] [Related]
6. CTLA-4 x Ig converts naive CD4+CD25- T cells into CD4+CD25+ regulatory T cells.
Razmara M; Hilliard B; Ziarani AK; Chen YH; Tykocinski ML
Int Immunol; 2008 Apr; 20(4):471-83. PubMed ID: 18272926
[TBL] [Abstract][Full Text] [Related]
7. Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces Foxp3+CD25+CD4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions.
Sun JB; Cuburu N; Blomquist M; Li BL; Czerkinsky C; Holmgren J
Scand J Immunol; 2006 Sep; 64(3):251-9. PubMed ID: 16918694
[TBL] [Abstract][Full Text] [Related]
8. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.
Terzieva V; Popova D; Kicheva M; Todorova Y; Markova R; Martinova F; Elenkov I; Yankova M
Int Immunopharmacol; 2009 Jul; 9(7-8):831-6. PubMed ID: 19303058
[TBL] [Abstract][Full Text] [Related]
9. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.
Nair S; Boczkowski D; Fassnacht M; Pisetsky D; Gilboa E
Cancer Res; 2007 Jan; 67(1):371-80. PubMed ID: 17210720
[TBL] [Abstract][Full Text] [Related]
10. Endothelial cells augment the suppressive function of CD4+ CD25+ Foxp3+ regulatory T cells: involvement of programmed death-1 and IL-10.
Bedke T; Pretsch L; Karakhanova S; Enk AH; Mahnke K
J Immunol; 2010 May; 184(10):5562-70. PubMed ID: 20382886
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells induced by rAAV carrying the forkhead box P3 gene prevent autoimmune thyroiditis in mice.
Wang S; Xu H; Wang Y; Ma J; Mao C; Shao Q; Ma B; Xu W; Yang S
Int J Mol Med; 2006 Dec; 18(6):1193-9. PubMed ID: 17089026
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of Foxp3 splice variants in human CD4+ and CD8+ T cells--identification of Foxp3Δ7 in human regulatory T cells.
Kaur G; Goodall JC; Jarvis LB; Hill Gaston JS
Mol Immunol; 2010; 48(1-3):321-32. PubMed ID: 20688398
[TBL] [Abstract][Full Text] [Related]
13. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes.
Tritt M; Sgouroudis E; d'Hennezel E; Albanese A; Piccirillo CA
Diabetes; 2008 Jan; 57(1):113-23. PubMed ID: 17928397
[TBL] [Abstract][Full Text] [Related]
14. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
[TBL] [Abstract][Full Text] [Related]
15. "Default" generation of neonatal regulatory T cells.
Wang G; Miyahara Y; Guo Z; Khattar M; Stepkowski SM; Chen W
J Immunol; 2010 Jul; 185(1):71-8. PubMed ID: 20498359
[TBL] [Abstract][Full Text] [Related]
16. Impaired T cell receptor signaling in Foxp3+ CD4 T cells.
Carson BD; Ziegler SF
Ann N Y Acad Sci; 2007 Apr; 1103():167-78. PubMed ID: 17376831
[TBL] [Abstract][Full Text] [Related]
17. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
[TBL] [Abstract][Full Text] [Related]
18. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
[TBL] [Abstract][Full Text] [Related]
19. Plasticity of T(reg) cells: is reprogramming of T(reg) cells possible in the presence of FOXP3?
Beyer M; Schultze JL
Int Immunopharmacol; 2011 May; 11(5):555-60. PubMed ID: 21115121
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
Schabowsky RH; Madireddi S; Sharma R; Yolcu ES; Shirwan H
Curr Opin Investig Drugs; 2007 Dec; 8(12):1002-8. PubMed ID: 18058571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
